drugset / Trial / NCT04277663
The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase III randomized, control, multi-center study of recombinant humanized anti-PD-1 mAb in combination with CTLA4 mAb for injection compared to high-Dose interferon in patients with acral melanoma that has been removed by surgery.
Timeline
- Start
- 2020-04-17
- Primary completion
- 2023-02-28
- Completion
- 2023-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI310 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Comparator | recombinant interferon a-2B | Protein / enzyme biologic | 9e+09 iu | Intravenous |